Sign up to save your podcasts
Or
Share FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab)
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab)
FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab)
View all episodes
By U.S. Food and Drug Administration, Center for Drug Evaluation and ResearchFDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab)